Antiviral and immunological benefits in HIV patients receiving intranasal peptide T (DAPTA)

Peptides

Volumn 24, Issue 7, 2003, Pages 1093-1098

  Polianova, Maria T ^a   Ruscetti, Francis W ^a   Pert, Candace B ^b   Tractenberg, Rochelle E ^b   Leoung, Gifford ^c   Strang, Scott ^c   Ruff, Michael R ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AIDS; Antiviral; CCR5; Chemokine receptor; Clinical trial; Cytotoxic T cells; Entry inhibitor; Peptide T; Viral reservoir

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; DEXTRO ALANINE PEPTIDE T AMIDE; GAMMA INTERFERON; PEPTIDE T; UNCLASSIFIED DRUG; VIRUS RNA;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; DRUG RESPONSE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INTERFERON PRODUCTION; LEUKOCYTE; LYMPHOCYTE COUNT; MONOCYTE; PATIENT; PRIORITY JOURNAL; RNA ANALYSIS; RNA REPLICATION; T LYMPHOCYTE; VIRUS CARRIER; VIRUS ISOLATION;

EID: 0141741416     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(03)00176-1     Document Type: Article

References (19)

1. Barbey-Morel C., McDonnell K., Pert C., Adams M., Farrand D., Ruff M.et al. A peptide T bolus normalizes growth hormone secretion pattern in two children with AIDS. Peptides. 6538:2002;1.
2. Barbour J.D., Wrin T., Grant R.M., Martin J.N., Segal M.R., Petropoulos C.J.et al. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J. Virol. 76:2002;11104.
3. Blankson J.N., Persaud D., Siliciano R.F. The challenge of viral reservoirs in HIV-1 infection. Annu. Rev. Med. 53:2002;557.
4. Condra J.H., Schleif W.A., Blahy O.M., Gabryelski L.J., Graham D.J., Quintero J.C.et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 374:1995;569.
5. Deeks S.G., Hoh R., Grant R.M., Wrin T., Barbour J.D., Narvaez A.et al. CD4+ T-cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. J. Infect. Dis. 185:2002;315.5.
6. Hammer S.M., Squires K.E., Hughes M.D., Grimes J.M., Demeter L.M., Currier J.S.et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N. Engl. J. Med. 337:1997;725.
7. Heseltine P.N., Goodkin K., Atkinson J.H., Vitiello B., Rochon J., Heaton R.K.et al. Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment. Arch. Neurol. 55:1998;41.
8. Kosten T.R., Rosen M.I., McMahon T.L., Bridge T.P., O'Malley S.S., Pearsall R.et al. Treatment of early AIDS dementia in intravenous drug users: high versus low dose peptide T. Am. J. Drug Alcohol Abuse. 23:1997;543.
9. Kovacs J.A., Vogel S., Metcalf J.A., Baseler M., Stevens R., Adelsberger J.et al. Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy. Eur. J. Immunol. 31:2001;1351.
10. Lacabaratz-Porret C., Urrutia A., Doisne J.M., Goujard C., Deveau C., Dalod M.et al. Impact of antiretroviral therapy and changes in virus load on human immunodeficiency virus (HIV)-specific T-cell responses in primary HIV infection. J. Infect. Dis. 187:2003;748.
11. Lambotte O., Taoufik Y., de_Goer M.G., Wallon C., Goujard C., Delfraissy J.F. Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. J. Acquir. Immune. Defic. Syndr. 23:2000;114.
12. McDonald C.K., Kuritzkes D.R. Human immunodeficiency virus type 1 protease inhibitors. Arch. Intern. Med. 157:1997;951.
13. Rhodes D.I., Ashton L., Solomon A., Carr A., Cooper D., Kaldor J.et al. Characterization of three nef-defective human immunodeficiency virus type 1 strains associated with long-term nonprogression. Australian long-term nonprogressor study group. J. Virol. 74:2000;10581.
14. Ruff M.R., Melendez-Guerrero L.M., Yang Q.E., Ho W.Z., Mikovits J.W., Pert C.B.et al. Peptide T inhibits HIV-1 infection mediated by the chemokine receptor-5 (CCR5). Antiviral Res. 52:2001;63.
15. Ruff M.R., Polianova M., Pert C.B., Ruscetti F.W. Update on D-Ala-Peptide T-Amide (DAPTA): a viral entry inhibitor that blocks CCR5 chemokine receptors. Curr. HIV Res. 1:2003;51.
16. Sonza S., Mutimer H.P., Oelrichs R., Jardine D., Harvey K., Dunne A.et al. Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy. AIDS. 15:2001;17.
17. Vesanen M., Stevens C.E., Taylor P.E., Rubinstein P., Saksela K. Stability in controlling viral replication identifies long-term nonprogressors as a distinct subgroup among human immunodeficiency virus type 1-infected persons. J. Virol. 70:1996;9035.
18. Villemagne V.L., Phillips R.L., Liu X., Gilson S.F., Dannals R.F., Wong D.F.et al. Peptide T and glucose metabolism in AIDS dementia complex. J. Nucl. Med. 37:1996;1177.
19. Wetterberg L., Alexius B., Saaf J., Sonnerborg A., Britton S., Pert C. Peptide T in treatment of AIDS [letter]. Lancet. 1:1987;159.